RecruitingNCT05227053

STOP AF First Post-Approval Study

STOP AF First Post-Approval Study, an Addendum to the Cryo Global Registry


Sponsor

Medtronic Cardiac Ablation Solutions

Enrollment

200 participants

Start Date

Apr 28, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The STOP AF First PAS is a prospective, global, multi-center, observational trial.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Subject has been diagnosed with symptomatic paroxysmal AF
  • Subject is ≥ 18 years of age or minimum age as required by local regulations
  • Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.
  • Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements

Exclusion Criteria7

  • History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1
  • Subjects under the following conditions may be included in the study:
  • Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of \<4 weeks prior to the index PVI procedure)
  • Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
  • A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.
  • Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)
  • Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager

Interventions

DEVICEArctic Front™ Cardiac Cryoablation Catheter

Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system


Locations(13)

Alaska Heart Institute

Anchorage, Alaska, United States

Cardiology Associates of Fairfield County

Stamford, Connecticut, United States

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

BayCare Medical Group Cardiology

Clearwater, Florida, United States

Heart Rhythm Solutions

Davie, Florida, United States

Iowa Heart

West Des Moines, Iowa, United States

Our Lady of the Lake

Baton Rouge, Louisiana, United States

Southcoast Health System

North Dartmouth, Massachusetts, United States

Henry Ford Heart & Vascular

Detroit, Michigan, United States

The Lindner Research Center

Cincinnati, Ohio, United States

Stern Cardiovascular Foundation

Germantown, Tennessee, United States

University of Tennessee Methodist Physicians

Memphis, Tennessee, United States

Texas Health Research and Education Institute

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05227053


Related Trials